Literature DB >> 12400011

Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade.

Rebecca L Pratt1, Michael S Kinch.   

Abstract

Intracellular signaling by receptor tyrosine kinases regulates many different aspects of cell behavior. Recent studies in our laboratory and others have demonstrated that the EphA2 receptor tyrosine kinase critically regulates tumor cell growth, migration and invasiveness. Although the cellular consequences of EphA2 signaling have been the focus of recent attention, the biochemical changes that are triggered by ligand-mediated activation of EphA2 remain largely unknown. Herein, we demonstrate that ligand stimulation of EphA2 promotes the nucleus translocation and phosphorylation of ERK kinases, followed by an increase in nuclear induction of the Elk-1 transcription factor. Ligand-mediated activation allows EphA2 to form a molecular complex with the SHC and GRB2 adaptor proteins. Specifically, we demonstrate that tyrosine phosphorylated EphA2 interacts with the PTB and SH2 domains of SHC. We also show that the interaction of EphA2 with GRB2 is indirect and mediated by SHC and that this complex is necessary for EphA2-mediated activation of ERK kinases. These studies provide a novel mechanism to demonstrate how EphA2 can convey information from the cell exterior to the nucleus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12400011     DOI: 10.1038/sj.onc.1205758

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  47 in total

Review 1.  Differential regulation of EphA2 in normal and malignant cells.

Authors:  Jennifer Walker-Daniels; Angela R Hess; Mary J C Hendrix; Michael S Kinch
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

Review 2.  Preclinical and clinical development of siRNA-based therapeutics.

Authors:  Gulnihal Ozcan; Bulent Ozpolat; Robert L Coleman; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

3.  Identification of phosphotyrosine binding domain-containing proteins as novel downstream targets of the EphA8 signaling function.

Authors:  Jongdae Shin; Changkyu Gu; Eunjeong Park; Soochul Park
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

4.  Alterations in the thymocyte phenotype of EphB-deficient mice largely affect the double negative cell compartment.

Authors:  David Alfaro; Juan José Muñoz; Javier García-Ceca; Teresa Cejalvo; Eva Jiménez; Agustín Zapata
Journal:  Immunology       Date:  2008-04-04       Impact factor: 7.397

5.  The SAM domain inhibits EphA2 interactions in the plasma membrane.

Authors:  Deo R Singh; Fozia Ahmed; Michael D Paul; Manasee Gedam; Elena B Pasquale; Kalina Hristova
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2016-10-21       Impact factor: 4.739

6.  Survival strategy of obligately intracellular Ehrlichia chaffeensis: novel modulation of immune response and host cell cycles.

Authors:  Jian-zhi Zhang; Mala Sinha; Bruce A Luxon; Xue-jie Yu
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 7.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

8.  A subset of signal transduction pathways is required for hippocampal growth cone collapse induced by ephrin-A5.

Authors:  Xin Yue; Cheryl Dreyfus; Tony Ah-Ng Kong; Renping Zhou
Journal:  Dev Neurobiol       Date:  2008-09-01       Impact factor: 3.964

9.  Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase.

Authors:  Wei Bin Fang; Dana M Brantley-Sieders; Yoonha Hwang; Amy-Joan L Ham; Jin Chen
Journal:  J Biol Chem       Date:  2008-04-03       Impact factor: 5.157

10.  Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth.

Authors:  David Kiewlich; Jianhuan Zhang; Cynthia Gross; Wei Xia; Brent Larsen; Ronald R Cobb; Sandra Biroc; Jian-Ming Gu; Takashi Sato; David R Light; Tara Heitner; Joerg Willuda; David Vogel; Felipe Monteclaro; Andrzej Citkowicz; Steve R Roffler; Deborah A Zajchowski
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.